SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (521)7/27/2019 5:01:35 PM
From: rkrw1 Recommendation

Recommended By
ghmm

  Read Replies (3) of 684
 
I can't remember the last biotech that did a simple dissolve and return the cash to shareholders.

Most failed bios can at least sell their shell and cash to a newco in a reverse merger. Going rate seems to be an absurd 30% premium to cash at least when a bio has a modest amount of cash. But you're counting on the failed management to find the best entity to trade their stock for. VICL last i checked was trading for about half ending cash even after picking a successor company, among other things, VICL management paid themselves fat cash bonuses in conjunction with the merger, kicking their shareholders in the teeth even on the way out.

All in all it's not difficult to spot which on the list would be actively seeking mergers and has nothing to do with CEO's age, generally it would already be publicly disclosed in 10Qs.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News